Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.

Johnson DR, Kimmel DW, Burch PA, Cascino TL, Giannini C, Wu W, Buckner JC

Neuro-oncology1 May 2011Cited by 69 (Europe PMC)

PMID21558077PMCIDPMC3093340DOI10.1093/neuonc/nor044PepBankPUB-21558077

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with recurrent meningeal tumors, octreotide produced no radiographic responses.
In plain wordsIn patients with recurrent meningeal tumors, octreotide produced no responses on scans.
Peptide
Octreotide
Outcome
Not applicableRadiographic response
Study
n = 12
Analysis
Primary
Outcome group
Tumor growth · Cancer
Studied dose
goal 500 μg 3 times per day, as tolerated · subcutaneousAs given in this study (human).
Source sentences
Summary
No radiographic responses were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II study was to evaluate the efficacy and safety of subcutaneous octreotide therapy for the treatment of recurrent meningioma and meningeal hemangiopericytoma.
Summary · context
Patients received subcutaneous octreotide with a goal dose of 500 μg 3 times per day, as tolerated.
Report a problemFND-2155807705
02HumanNon-randomized trialSafety outcome
In patients with recurrent meningeal tumors receiving octreotide, diarrhea occurred at grade 1 in 4 patients and grade 2 in 2.
In plain wordsIn patients with recurrent meningeal tumors receiving octreotide, diarrhea affected four patients at grade one and two at grade two.
Peptide
Octreotide
Outcome
Not applicableDiarrhea
Study
n = 12
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
goal 500 μg 3 times per day, as tolerated · subcutaneousAs given in this study (human).
Measurements
Diarrhea grade 1
4 patients
octreotide
Diarrhea grade 2
2 patients
octreotide
Source sentences
Summary
Side effects included diarrhea (grade 1 in 4 patients and grade 2 in 2), nausea or anorexia (grade 1 in 4 patients), and transaminitis (grade 1 in 1 patient).
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II study was to evaluate the efficacy and safety of subcutaneous octreotide therapy for the treatment of recurrent meningioma and meningeal hemangiopericytoma.
Summary · context
Patients received subcutaneous octreotide with a goal dose of 500 μg 3 times per day, as tolerated.
Report a problemFND-2155807701
03HumanNon-randomized trialSafety outcome
In patients with recurrent meningeal tumors receiving octreotide, grade 1 nausea or anorexia occurred in 4 patients.
In plain wordsIn patients with recurrent meningeal tumors receiving octreotide, four patients had mild nausea or appetite loss.
Peptide
Octreotide
Outcome
Not applicableNausea or anorexia
Study
n = 12
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
goal 500 μg 3 times per day, as tolerated · subcutaneousAs given in this study (human).
Measurements
Nausea or anorexia grade 1
4 patients
octreotide
Source sentences
Summary
Side effects included diarrhea (grade 1 in 4 patients and grade 2 in 2), nausea or anorexia (grade 1 in 4 patients), and transaminitis (grade 1 in 1 patient).
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II study was to evaluate the efficacy and safety of subcutaneous octreotide therapy for the treatment of recurrent meningioma and meningeal hemangiopericytoma.
Summary · context
Patients received subcutaneous octreotide with a goal dose of 500 μg 3 times per day, as tolerated.
Report a problemFND-2155807702
04HumanNon-randomized trialSafety outcome
In patients with recurrent meningeal tumors receiving octreotide, grade 1 transaminitis occurred in 1 patient.
In plain wordsIn patients with recurrent meningeal tumors receiving octreotide, one patient had mildly elevated liver enzymes.
Peptide
Octreotide
Outcome
Not applicableTransaminitis
Study
n = 12
Outcome group
Adverse events · Liver
Studied dose
goal 500 μg 3 times per day, as tolerated · subcutaneousAs given in this study (human).
Measurements
Transaminitis grade 1
1 patients
octreotide
Source sentences
Summary
Side effects included diarrhea (grade 1 in 4 patients and grade 2 in 2), nausea or anorexia (grade 1 in 4 patients), and transaminitis (grade 1 in 1 patient).
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II study was to evaluate the efficacy and safety of subcutaneous octreotide therapy for the treatment of recurrent meningioma and meningeal hemangiopericytoma.
Summary · context
Patients received subcutaneous octreotide with a goal dose of 500 μg 3 times per day, as tolerated.
Report a problemFND-2155807703
05HumanNon-randomized trialSafety outcome
One patient receiving octreotide developed extra hepatic cholangiocarcinoma, which was likely unrelated to therapy.
In plain wordsOne patient receiving octreotide developed bile duct cancer, which was likely unrelated to treatment.
Peptide
Octreotide
Outcome
Not applicableExtra hepatic cholangiocarcinoma
Study
n = 12
Outcome group
Adverse events · Cancer
Studied dose
goal 500 μg 3 times per day, as tolerated · subcutaneousAs given in this study (human).
Measurements
Extra hepatic cholangiocarcinoma
1 patients
octreotide; likely unrelated to octreotide per source
Source sentences
Summary
One patient developed extra hepatic cholangiocarcinoma, which was likely unrelated to octreotide therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II study was to evaluate the efficacy and safety of subcutaneous octreotide therapy for the treatment of recurrent meningioma and meningeal hemangiopericytoma.
Summary · context
Patients received subcutaneous octreotide with a goal dose of 500 μg 3 times per day, as tolerated.
Report a problemFND-2155807704
06HumanNon-randomized trialEfficacy outcome
Among 12 patients receiving octreotide for recurrent meningeal tumors, 11 progressed, with median time to progression of 17 weeks.
In plain wordsAmong twelve patients receiving octreotide for recurrent meningeal tumors, eleven progressed, with a median progression time of seventeen weeks.
Peptide
Octreotide
Outcome
Not applicableProgression and time to progression
Study
n = 12
Outcome group
Tumor growth · Cancer
Studied dose
goal 500 μg 3 times per day, as tolerated · subcutaneousAs given in this study (human).
Measurements
Patients with progression
11 patients
of 12 enrolled
Median time to progression
17 weeks
octreotide
Source sentences
Summary
Eleven of the 12 patients experienced progression, with a median time to progression of 17 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II study was to evaluate the efficacy and safety of subcutaneous octreotide therapy for the treatment of recurrent meningioma and meningeal hemangiopericytoma.
Summary · context
Patients received subcutaneous octreotide with a goal dose of 500 μg 3 times per day, as tolerated.
Report a problemFND-2155807706
07HumanNon-randomized trialSafety outcome
Eleven patients receiving octreotide for recurrent meningeal tumors died.
In plain wordsEleven patients receiving octreotide for recurrent meningeal tumors died.
Peptide
Octreotide
Outcome
Not applicableDeaths
Study
n = 12
Outcome group
Mortality · Cancer
Studied dose
goal 500 μg 3 times per day, as tolerated · subcutaneousAs given in this study (human).
Measurements
Deaths
11 patients
of 12 enrolled; octreotide cohort, no causal attribution in source
Source sentences
Summary
Eleven patients have died.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II study was to evaluate the efficacy and safety of subcutaneous octreotide therapy for the treatment of recurrent meningioma and meningeal hemangiopericytoma.
Summary · context
Patients received subcutaneous octreotide with a goal dose of 500 μg 3 times per day, as tolerated.
Report a problemFND-2155807708
08HumanNon-randomized trialEfficacy outcome
Patients receiving octreotide for recurrent meningeal tumors had median survival of 2.7 years.
In plain wordsPatients receiving octreotide for recurrent meningeal tumors had median survival of 2.7 years.
Peptide
Octreotide
Outcome
Not applicableMedian survival
Study
n = 12
Outcome group
Mortality · Cancer
Studied dose
goal 500 μg 3 times per day, as tolerated · subcutaneousAs given in this study (human).
Measurements
Median survival
2.7 years
octreotide cohort
Source sentences
Summary
Median duration of survival was 2.7 years.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II study was to evaluate the efficacy and safety of subcutaneous octreotide therapy for the treatment of recurrent meningioma and meningeal hemangiopericytoma.
Summary · context
Patients received subcutaneous octreotide with a goal dose of 500 μg 3 times per day, as tolerated.
Report a problemFND-2155807709
09HumanNon-randomized trialEfficacy outcome
Two patients receiving octreotide for recurrent meningeal tumors had progression-free intervals of 30 months and ≥18 years.
In plain wordsTwo patients receiving octreotide for recurrent meningeal tumors remained free from progression for thirty months and at least eighteen years.
Peptide
Octreotide
Outcome
Not applicableLong progression-free intervals
Study
n = 2
Outcome group
Tumor growth · Cancer
Studied dose
goal 500 μg 3 times per day, as tolerated · subcutaneousAs given in this study (human).
Measurements
Progression-free interval, patient 1
30 months
octreotide
Progression-free interval, patient 2
≥ 18 years
octreotide; source says ≥18 years
Source sentences
Summary
Two patients experienced long progression-free intervals (30 months and ≥18 years).
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II study was to evaluate the efficacy and safety of subcutaneous octreotide therapy for the treatment of recurrent meningioma and meningeal hemangiopericytoma.
Summary · context
Patients received subcutaneous octreotide with a goal dose of 500 μg 3 times per day, as tolerated.
Report a problemFND-2155807707

Studies that did not test the peptide alone1

In this study, Octreotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Octreotide.

10HumanNot a test of Octreotide aloneObservational studyOther
In an octreotide-treated meningeal tumor subset, Sstr2a expression did not correlate with progression-free survival length.
In plain wordsIn an octreotide-treated meningeal tumor subset, receptor expression showed no link with time without progression.
Peptide
Octreotide
Outcome
No significant changeSstr2a expression and progression-free survival
Study
n: not reported in source
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Immunohistochemical staining of somatostatin receptor Sstr2a expression in a subset of patients did not reveal a correlation between level of expression and length of progression-free survival.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this phase II study was to evaluate the efficacy and safety of subcutaneous octreotide therapy for the treatment of recurrent meningioma and meningeal hemangiopericytoma.
Summary · context
Patients received subcutaneous octreotide with a goal dose of 500 μg 3 times per day, as tolerated.
In this study, Octreotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Octreotide.
Report a problemFND-2155807710

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.